Featured sources, Feb. 21

  • Bloomberg’s COVID-19 Vaccine Tracker: We’ve featured Bloomberg’s tracker in the CDD before (in fact, you can read Drew Armstrong’s walkthrough of the dashboard here), but it’s worth highlighting that the Bloomberg team made two major updates this week. First, they added a demographic vertical, which includes race and ethnicity data for the U.S. overall and for 27 states that are reporting these data. This vertical will be updated weekly. Second, the team made all of their data available on GitHub! I, for one, am quite excited to dig through the historical figures.
  • CoVariants: This new resource from virus tracker Dr. Emma Hodcroft provides an overview of SARS-CoV-2 variants and mutations. You can explore how variants have spread across different parts of the world through brightly colored charts. The resource is powered by GISAID, Nextstrain, and other sequencing data; follow Dr. Hodcroft on Twitter for regular updates.
  • The Next Phase of Vaccine Distribution: High-Risk Medical Conditions (from KFF): The latest analysis brief from the Kaiser Family Foundation looks at how individuals with high-risk medical conditions are being prioritized for vaccine distribution in each state. KFF researchers compared each state’s prioritization plans to the CDC’s list of conditions that “are at increased risk” or “may be at an increased risk” for severe illness due to COVID-19; the analysis reflects information available as of February 16.
  • First Month of COVID-19 Vaccine Safety Monitoring (CDC MMWR): This past Friday, the CDC released a Morbidity and Mortality Weekly Report with data from the first month of safety monitoring, using the agency’s Vaccine Adverse Event Reporting System (or VAERS). Out of the 13.8 million vaccine doses administered during this period, about 7,000 adverse events were reported—and only 640 were classified as serious. Check the full report for figures on common side effects and enrollment in the CDC’s new v-safe monitoring program.

Leave a Reply